Parabilis is teeing up the latest high-profile stock issuance in a year when biotech IPOs are averaging more than $286 ...

Regeneron Pharmaceuticals will partner with Parabilis Medicines to discover and develop an initial five candidates ...

Regeneron Pharmaceuticals REGN has entered into a strategic research collaboration with clinical-stage biopharmaceutical ...

Parabilis Medicines today announced a strategic research collaboration with Regeneron Pharmaceuticals, Inc. to discover and ...

Regeneron has announced a strategic research collaboration with Parabilis Medicines to discover and develop multiple ...

Regeneron and Parabilis Medicines partner to discover and develop antibody-Helicon conjugates, aiming to create a new class ...

Add Yahoo as a preferred source to see more of our stories on Google. Proteasomes are molecular machines for breaking down proteins. Drugmakers are working to coopt this process with targeted ...

The Stagljar Lab is a global leader in proteomics and chemical genomics, specializing in unraveling protein-protein interactions of human membrane proteins. Pivotal in cancer and rare genetic diseases ...

The term 'undruggable' refers to proteins or targets that are challenging to target with conventional drugs. In recent years, researchers have made progress in developing drugs that can interact with ...

The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon™ peptide platform Agreement provides for Parabilis to receive $125M from ...